SC Slams 10x Cancer Drug Markup: Carnage for Patients
The Supreme Court of India recently condemned the steep cancer drug markup practiced by corporate hospitals. Specifically, the apex court termed the ten-fold price inflation on life-saving oncology medicines sheer carnage. A division bench comprising Justice Vikram Nath and Justice Sandeep Mehta observed that this system severely harms common patients. Furthermore, the judges highlighted that inflated maximum retail prices exhaust family savings rapidly. Therefore, the judiciary pressed the Union Government to introduce a uniform regulatory margin on all essential formulations.
The Ten-Fold Cancer Drug Markup Under Judicial Scrutiny
During the proceedings, the bench scrutinized stark disparities between hospital procurement costs and retail prices. For instance, an essential cancer drug reaches retailers at a price of 2,700 rupees. However, private hospitals sell the identical drug to desperate patients at an MRP of 27,000 rupees. The court questioned where this enormous twenty-four-thousand-rupee profit goes. In addition, the judges remarked that healthcare facilities often prevent families from retrieving deceased patients until they settle bills. Solicitor General Tushar Mehta acknowledged the gravity of the pricing crisis. Moreover, he noted that private healthcare establishments, rather than manufacturers, capture the bulk of these gains. Consequently, the Centre agreed to consult healthcare authorities to establish equitable pricing boundaries.
Examining DPCO Regulations and Pharmacy Monopolies
The Supreme Court also examined structural flaws within the Drugs Prices Control Order, known as DPCO 2013. Currently, the National Pharmaceutical Pricing Authority enforces ceiling prices on scheduled drugs. Nevertheless, non-scheduled formulations represent over eighty percent of the market and lack upfront price caps. The bench proposed capping the trade margin at a uniform sixteen percent across all pharmaceutical products. Furthermore, the court criticized hospitals for compelling patients to buy supplies exclusively from internal pharmacies. When patients obtain medicines externally, facilities often deny treatment assurance. Ultimately, this practice inflates reimbursements under public schemes like Ayushman Bharat, draining honest taxpayer funds.
Clinical Implications and Prescription Ethics for Doctors
This landmark judicial scrutiny carries direct implications for practicing oncologists and institutional physicians across India. Public interest litigations demand strict disciplinary enforcement against doctors who fail to prescribe generic formulations. Therefore, clinicians must prioritize transparent prescribing to reduce financial toxicity for oncology patients. When physicians mandate proprietary brands without clear bioequivalence advantages, they unintentionally compound financial strain. In contrast, rational prescribing protects families from catastrophic healthcare expenditure. Clinicians must actively champion institutional transparency and resist predatory drug markups. Thus, medical professionals play an indispensable role in safeguarding patient welfare and medical ethics.
Frequently Asked Questions
Q1: Why did the Supreme Court label oncology drug markups as carnage?
The bench used this term after learning that oncology drugs costing 2,700 rupees carry an MRP of 27,000 rupees. Consequently, this excessive markup burdens vulnerable families and depletes state healthcare funds.
Q2: What margin cap did the Supreme Court propose for medicines?
The court recommended exploring a uniform sixteen percent profit margin on the maximum retail price of all medications. Therefore, this policy would eliminate disparities between scheduled and non-scheduled drug pricing.
Q3: How do in-house hospital pharmacies affect patient expenditure?
Many private hospitals mandate purchases strictly through their own pharmacies, preventing patients from accessing discounted outside retailers. As a result, patients pay steep retail prices, and public welfare insurance programs face inflated reimbursement claims.
References
- 'This is carnage', says SC on markup of 10 times on cancer drugs by hospitals - ETHealthworld
- Supreme Court questions steep mark-ups on cancer drugs, calls pricing disparity 'carnage' - The Hindu
- Impact of the Drug Prices Control Order (2013) on the Utilization of Anticancer Medicines in India: An Interrupted Time-Series Analysis - PMC
